Key Drivers
- Improving Margins
- Cash Burn
- Leverage Pressure
AIAI Summary
QDEL is no longer a clean recovery story but a stressed turnaround where modest ex-China and segment strength is overshadowed by cut guidance, withdrawn free cash flow targets, and heavy cash burn against high leverage, so investors should treat it as a “prove stabilization first” name rather than a buy-the-dip setup.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improving Margins
- •Cash Burn
- •Leverage Pressure
QDEL shows improving quarterly operating performance and a cheap-looking valuation, but persistent net losses, negative free cash flow, and heavy leverage keep the stock under pressure.
Price Behavior
Key Price Behavior Insights:
- •Near-term support
- •Overhead resistance
- •High volatility
QDEL remains weak over the last month despite a bounce off $12.29, with $15.09 acting as near-term support, $16.32–$17.71 as overhead resistance, and high volatility keeping the short-term setup fragile.
Sharp drop from $17.71 to $12.29 signals elevated volatility and risk
Sentiment & News
Key News Insights:
- •Outlook cut
- •China weakness
- •Share pressure
QuidelOrtho beat Q2 estimates but cut its 2026 outlook and withdrew free cash flow guidance as China weakness and softer respiratory demand offset growth in Labs/Point of Care, pressuring the shares amid added legal overhang.
The stock likely stays under pressure until management shows clearer demand stabilization and a more credible path to restored guidance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings